List of Beyaz drug patents

Beyaz is owned by Bayer Hlthcare.

Beyaz contains Drospirenone; Ethinyl Estradiol; Levomefolate Calcium.

Beyaz has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Beyaz are:

  • US7163931
  • US6441168

Beyaz was authorised for market use on 24 September, 2010.

Beyaz is available in tablet;oral dosage forms.

Beyaz can be used as prevention of pregnancy.

The generics of Beyaz are possible to be released after 08 February, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Jul, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(11 months ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(7 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: Prevention of pregnancy

Dosage: TABLET;ORAL

How can I launch a generic of BEYAZ before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic